Enhancement of radiation and chemotherapeutic drug responses by 2-deoxy-D-glucose in animal tumors

J Cancer Res Ther. 2009 Sep;5 Suppl 1:S16-20. doi: 10.4103/0973-1482.55135.

Abstract

The development of an approach based on the energy-linked modification of DNA repair and cellular recovery processes using 2-deoxy-D-glucose (2-DG; inhibitor of glycolytic ATP production) has shown promising results in a number of model systems of cancer. Following encouraging results on the tolerance and toxicity (acute as well as late effects) of the combination (2-DG and hypofractionated radiotherapy) in Phase I and II clinical trials, its efficacy is currently under evaluation in Phase III clinical trials for glioma patients. Since heterogeneous physiologic and metabolic status in tumors as well as host-tumor interactions influence the local tumor control, which coupled with systemic disturbances could determine the cure (long-term tumor free survival), investigations on the in vivo responses of tumors to the combined treatment have received considerable attention. This communication provides a brief overview on the in vivo studies related to radio- and chemosensitization of tumors by 2-DG, besides the normal tissue toxicity induced by the combined treatment of 2-DG and radiation or chemotherapeutic drugs.

Publication types

  • Review

MeSH terms

  • Animals
  • Antineoplastic Combined Chemotherapy Protocols / pharmacology*
  • Combined Modality Therapy
  • Deoxyglucose / administration & dosage*
  • Glucose / metabolism
  • Neoplasms, Experimental / metabolism*
  • Neoplasms, Experimental / therapy*
  • Radiotherapy / methods*

Substances

  • Deoxyglucose
  • Glucose